Clinical trial
GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or…
NCT00074022 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00074022 |
|---|---|
| Title | GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors |
| Official title | A Phase I/2 Study of GTI-2040 Combined With Docetaxel In Metastatic Or Unresectable Locally Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Non-small Cell Lung Cancer, Recurrent Prostate Cancer, Stage III Prostate Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological, Drug, Other |
| Interventions | GTI-2040, docetaxel, laboratory biomarker analysis, pharmacological study |
| Enrollment | 48 |
| Start date | Oct 1, 2003 |
| Primary completion | Nov 1, 2007 |
| First posted | Dec 11, 2003 |
| Last update posted | Jan 24, 2013 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: